在非小细胞肺癌中osimerinib的血液毒性:随机对照试验的元分析
Fangfang Xiong1, Yunzhu Shen1, Ting Liu1
1Department of Pharmacy, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China.
BMJ supportive & palliative care
|August 19, 2024
概括
对于非小细胞肺癌 (NSCLC) 的奥西默蒂尼布治疗可能会导致显著的血液毒性,包括贫血,中性质衰竭和血小板衰竭. 这些副作用,特别是高度事件,需要对NSCLC患者进行仔细的监测和管理.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 血液学 血液学 血液学
背景情况:
- 奥西默提尼布是治疗非小细胞肺癌 (NSCLC) 的重要治疗方法.
- 与 osimertinib 相关的血液毒性尚未完全理解.
- 鉴别这些毒性对患者安全至关重要.
研究的目的:
- 为了确定与奥西默蒂尼布相关的血液毒性在NSCLC患者的发生率.
- 量化贫血,中性质衰竭和血小板衰竭的风险.
- 为了向临床实践提供有关 osimertinib 使用的信息.
主要方法:
- 在主要数据库 (PubMed,Embase,Cochrane图书馆,Web of Science) 进行了全面的文献搜索.
- 包括了报告在NSCLC患者中因奥西默提尼布引起的血液毒性的符合条件的研究.
- 计算了贫血,中性质衰竭和血小板衰竭的综合发病率.
主要成果:
- 这项研究分析了10项研究中的1288名患者的数据.
- 总体发生率为:贫血 (21.1%),中性质减退 (14.6%) 和血小板减退 (28.4%).
- 在较低的比率中观察到高度毒性:贫血 (0.5%),中性质减退 (2.0%) 和血小板减少 (0.4%).
结论:
- 奥西默提尼布与不可忽视的血液毒性有关.
- 贫血,中性缺血和血小板缺血是关键问题.
- 这些毒性要求在临床环境中认真考虑和主动管理.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.9K
07:59Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
1.0K
相关概念视频
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:21Cancer Survival Analysis
334
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
334